Literature DB >> 14665346

Racial disparity in incidence patterns and outcome of kidney cancer.

U N Vaishampayan1, H Do, M Hussain, K Schwartz.   

Abstract

OBJECTIVES: To identify the subgroups that primarily contribute to the greater incidence and mortality of renal cancer in black Americans compared with white Americans.
METHODS: We analyzed age, stage, and race-related differences in the incidence and survival among patients with renal cancer using the national Surveillance, Epidemiology, and End Results (SEER) registry database. White and black patients with renal cell carcinoma who were older than 19 years of age and had been diagnosed between 1975 and 1998 were included. Incidence trends were analyzed by joinpoint regression with the statistical significance level at P <0.05. The Cox proportional hazards model was used to determine the overall survival of patients with renal cell carcinoma by race (white versus black), age (20 to 59 versus 60+ years), and stage (local versus regional/distant).
RESULTS: Localized disease predominantly accounted for the rise in incidence. Both black age groups with localized disease had a greater estimated annual percentage of incidence increase (4.46% for 20 to 59 years and 4.35% for 60+ years) compared with their white counterparts (2.87% and 3.06%, respectively). The magnitude of survival difference was largest between black versus white patients younger than 60 years of age who had local stage disease, with a median survival time of 190 and 259 months, respectively (P <0.0001).
CONCLUSIONS: Young black patients with localized renal cancer appear to have had a greater rise in incidence and a poorer outcome than white patients of the same age and disease stage. Additional investigation is warranted to define the role of these race, stage, and age-related disparities in the etiology, prognosis, treatment, and follow-up of kidney cancer.

Entities:  

Mesh:

Year:  2003        PMID: 14665346     DOI: 10.1016/j.urology.2003.07.010

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  26 in total

1.  Renal cancer paradox: higher incidence but not higher mortality among African-Americans.

Authors:  Loren Lipworth; Joseph K McLaughlin; Robert E Tarone; William J Blot
Journal:  Eur J Cancer Prev       Date:  2011-07       Impact factor: 2.497

2.  Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival.

Authors:  Helen Shi Stafford; Sidney L Saltzstein; Suzuho Shimasaki; Catherine Sanders; Tracy M Downs; Georgia Robins Sadler
Journal:  J Urol       Date:  2008-03-17       Impact factor: 7.450

3.  Kidney cancer incidence and mortality among American Indians and Alaska Natives in the United States, 1990-2009.

Authors:  Jun Li; Hannah K Weir; Melissa A Jim; Sallyann M King; Reda Wilson; Viraj A Master
Journal:  Am J Public Health       Date:  2014-04-22       Impact factor: 9.308

Review 4.  IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.

Authors:  Alexandra Kirner; Andrea Mayer-Mokler; Carsten Reinhardt
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

5.  Hospital-level variation in the quality of urologic cancer surgery.

Authors:  John L Gore; Jonathan L Wright; Kenn B Daratha; Kenneth P Roberts; Daniel W Lin; Hunter Wessells; Michael Porter
Journal:  Cancer       Date:  2011-07-26       Impact factor: 6.860

6.  Trends in the use of cytoreductive nephrectomy in the United States.

Authors:  Che-Kai Tsao; Alexander C Small; Erin L Moshier; Benjamin A Gartrell; Juan P Wisnivesky; Guru Sonpavde; James H Godbold; Michael A Palese; Simon J Hall; William K Oh; Matthew D Galsky
Journal:  Clin Genitourin Cancer       Date:  2012-05-30       Impact factor: 2.872

7.  Contemporary clinical epidemiology of renal cell carcinoma: insight from a population based case-control study.

Authors:  David C Miller; Julie Ruterbusch; Joanne S Colt; Faith G Davis; W Marston Linehan; Wong-Ho Chow; Kendra Schwartz
Journal:  J Urol       Date:  2010-10-16       Impact factor: 7.450

8.  Disparities in the treatment of patients with IL-2 for metastatic renal cell carcinoma.

Authors:  Christopher S Saigal; Christopher M Deibert; Julie Lai; Matthias Schonlau
Journal:  Urol Oncol       Date:  2008-12-12       Impact factor: 3.498

9.  Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis.

Authors:  Che-kai Tsao; Alexander C Small; Max Kates; Erin L Moshier; Juan P Wisnivesky; Benjamin A Gartrell; Guru Sonpavde; James H Godbold; Michael A Palese; Simon J Hall; William K Oh; Matthew D Galsky
Journal:  World J Urol       Date:  2012-12-08       Impact factor: 4.226

10.  Contemporary epidemiology of renal cell cancer.

Authors:  Wong-Ho Chow; Susan S Devesa
Journal:  Cancer J       Date:  2008 Sep-Oct       Impact factor: 3.360

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.